Subscribe To
Replimune Announces Pricing of Public Offering
BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of $23.50 per share. In addition, in lieu […] The post Replimune Announces Pricing of Public Offering appeared first on ForexTV...
Read More
Posted: Dec 9 2022, 02:04
Author Name: forextv
Views: 110716